DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Immune checkpoint inhibitors have taken the oncology space by storm and there's a lot of excitement about their potential across a wide range of indications, including in difficult-to-treat cancers. As drug developers turn to combinatorial approaches to get an edge in this competitive environment, market access and cost will be key variables that will shape uptake of immunotherapy-based combinations.

Khurram Nawaz, M.Sc., is a Director in the oncology division at Decision Resources Group.

He has expertise across a wide range of indications and topics, including prostate cancer, multiple myeloma and other hematological malignancies, and cancer immunotherapies.

Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders.

He holds a M.Sc. in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a B.Sc. in life sciences from the Pierre and Marie Curie-Paris VI University.

Available as a speaker

Contact Us About Your Event